InvestorsHub Logo
Followers 22
Posts 1570
Boards Moderated 0
Alias Born 01/17/2019

Re: ggwpq post# 202348

Friday, 07/19/2019 12:56:52 PM

Friday, July 19, 2019 12:56:52 PM

Post# of 427641

The $6.4B question is did Amarin, whether on its own or at FDA's request, had submitted additional data since 3/28/2019, that constitute a major amendment to the sNDA. I hope not, otherwise 3-month PDUFA delay.



Amarin IR refused to answer this question:


Q1a:Has Amarin submitted any data to the FDA, either on your own initiative or at the FDA's behest, since the original 3/28/2019 sNDA filing?

A1a: As part of the normal sNDA submission process, Amarin does work with the FDA to provide necessary information.

I cannot comment on the specifics around the communication processes.



Q1b: I understand that communication is ongoing -- however, my questions pertains as to whether any formal addendum(s) to the sNDA submission have been formally transmitted... i.e. above and beyond normal communication that is inherent to the sNDA process.

A1b: We are not commenting on the FDA communication.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News